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Abstract
Objective—Prostate cancer is the second most common cancer among men in the world.
Although some nutrients have been linked to the development of total prostate cancer, it remains
unclear whether these nutrients modulate the risk of its clinical significant form – advanced tumor.
Therefore, this study sought to perform a systematic review of the literature on this topic.
Methods—The papers reviewed were identified from PubMed by searching key words, diet and
advanced, metastatic, or lethal prostate cancer. A total of 46 papers published until September
2012 met our eligibility criteria and thus were evaluated in this review.
Results—Epidemiologic studies have overall showed that the habitual consumption of a diet
high in saturated fat, well-done meats, and calcium is associated with an increased risk of
advanced prostate cancer. An inconsistent association was observed for intakes of total meat,
fruits, and vegetables. Although most case-control studies suggest that intakes of these nutrients or
foods significantly alter advanced prostate cancer risk, cohort studies yielded mixed results. No
apparent effect of fish and zinc intake on advanced prostate cancer was found in most
epidemiologic studies.
Conclusions—Epidemiologic studies conducted to date have revealed that some dietary factors
modulate the risk of advanced prostate cancer. If these findings are confirmed by more
adequately-powered epidemiologic studies, especially prospective cohort studies that measure the
nutrients and their biochemical indicators, the risk of advanced prostate cancer, which is fatal and
thus clinically significant, may be reduced by dietary modification or chemoprevention.
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Introduction
Prostate cancer is a leading cause of cancer death in most developed countries and an
emerging public health problem in developing countries (Jemal et al., 2011). On the global
level, prostate cancer is the second most commonly diagnosed cancer and the sixth leading
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cause of cancer death among men (Jemal et al., 2011). To date, however, the etiology of this
malignancy remains unclear, with age, race, and family history as the only well-established
risk factors (Hsing and Devesa, 2001; Leitzmann and Rohrmann, 2012).
Ecologic and migrant studies have offered substantial evidence that dietary factors may play
a role in the etiology of prostate cancer (Rose et al., 1986). Specifically, populations with
high intake of saturated fat and red meats have an increased risk of prostate cancer compared
with populations with low intake of these nutrients or food items (Ma and Chapman, 2009;
Michaud et al., 2001; Rose et al., 1986). Remarkable increase in the risk of this disease has
been observed after men in East Asia immigrated to North America (Whittemore et al.,
1995). Prostate cancer incidence rates have been rapidly increasing in China, Korea, Japan,
and Singapore during the last several decades (Zhang et al., 2012). This upward change has
been primarily ascribed to the occurrence of nutrition transition in these countries during the
same period of time (Zhang et al., 2012). Nutrition transition is defined by a gradual change
towards the Westernized diet characterized by high intake of energy, animal fat, and meats
and low intake of fiber (Zhang et al., 2012). Although aforementioned descriptive
epidemiologic studies suggest that dietary habits influence the risk of prostate cancer, case-
control and cohort studies have provided mixed results on dietary etiology of this
malignancy (Michaud et al., 2001; Zhu et al., 2005).
Prostate cancer can be either indolent or aggressive. While indolent tumors may remain
asymptomatic for a whole life, aggressive tumors can rapidly progress to advanced disease
(Brassell et al., 2011). A growing body of evidence suggests that these two types of prostate
cancer have a different etiology (Rose, 1997). One of the potential reasons for inconsistent
results of case-control and cohort studies examining the association between diet and
prostate cancer may be that most of these studies had a small number of advanced tumors.
Given the clinical importance of advanced prostate cancer, it is crucial to understand which
nutrients, foods, or food groups significantly modulate the risk of its occurrence. Therefore,
this paper sought to review the current evidence of epidemiologic studies on this topic.
Materials and Methods
A PubMed search of published papers was conducted through September 2012 to identify
studies eligible for review. A total of 280 papers were found when keywords ‘diet’ and
‘advanced prostate cancer’; ‘diet’ and ‘lethal prostate cancer’; and ‘diet’ and ‘metastatic
prostate cancer’ were used. A paper was eligible for review if it reported separate risk
estimates [odds ratio (OR) or relative risk (RR)] for advanced, lethal, or metastatic prostate
cancer. The abstracts of all these papers were reviewed to determine whether they met the
inclusion criteria. When an abstract did not provide sufficient information for this eligibility
evaluation, its full paper was examined instead. Studies were excluded if they were
published as a review paper or reported in the form of an abstract only. To ensure the
adequacy of published data for review, we only examined the nutrients, foods, or food
groups that have been investigated in relation to risk of advanced prostate cancer in at least
three independent studies. The nutrients, foods, or food groups that met this criterion are
meat and meat products, fat, calcium, dairy products, fruits and vegetables, lycopene,
vitamins, fish, zinc, and dietary patterns.
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The following information was extracted from each of eligible papers: author(s), publication
year, study population, study design, geographical location, sample size, dietary assessment
methods, risk estimates [(OR or RR) and 95% confidence intervals (95% CI)], and
confounders controlled for in multiple regression analysis. If more than one paper was
published using data collected from the same study, the paper that analyzed most recent data
or had the largest (or larger) sample size was included in this review.
Results
The dietary factors reviewed for their associations with the risk of advanced prostate cancer
included meat and meat products (Table 1), fat (Table 2), calcium, vitamin D, and dairy
products (Table 3), fruits, vegetables, and vitamins (Table 4), lycopene and tomato products
(Table 5), and fish and other dietary factors. Lycopene abounds in tomatoes and tomato
products (Giovannucci, 1999). The results of epidemiologic studies evaluating the effects of
tomatoes and tomato products on advanced prostate cancer were presented in a separate
table because a large number of studies have investigated this association. The results shown
in all tables are risk estimates (ORs or RRs) comparing the highest with the lowest intake
categories of nutrients or foods.
1. Meat and Meat products
Case-Control Studies—Most case-control studies showed inconsistent associations
between meat intake and the risk of advanced prostate cancer, whereas the promoting effect
was overall consistent across studies for intakes of well-done meats and suspected
carcinogens derived from the meats cooked in this manner (Table 1). In a population-based
case-control study, total meat and white meat consumption was not associated with the risk
of advanced prostate cancer (John et al., 2011), but a significantly progressively elevated
risk of advanced prostate cancer were observed for higher intake of hamburgers (p-trend =
0.02) (John et al., 2011). In another study, intake of red meat, hamburger, steak, poultry,
sausage, processed meat and bacon did not alter advanced prostate cancer risk (Joshi et al.,
2012).
A number of suspected mutagens or carcinogens are produced when meats are cooked at
high temperature (Gu et al., 2010; Sinha et al., 1998; Sugimura et al., 2004). Depending on
the types of meat and level of doneness, the mutagens detected in cooked meat include:
heterocyclic amines [e.g. 2-amino-1-methyl1–6-phenylimidazo[4,5-b]pyridine (PhIP), 2-
amino-3,8-dimethylimidazo-[4,5-b]quinoxaline (MeIQx), and 2-amino-3, 4,8-
trimethylimidazo-[4,5-f]quinoxaline (DiMeIQx), and polycyclic aromatic hydrocarbons [e.g.
benzo(a)pyrene (BaP)] (Gu et al., 2010; Sinha et al., 1998; Sugimura et al., 2004). One
study has demonstrated a marginally significant association between PhIP intake and the
risk of advanced prostate cancer [OR (95% CI): 1.2 (0.9, 1.6), for quintile 5 vs. quintile 1]
(Joshi et al., 2012). In addition, intakes of red meat [OR (95% CI): 1.4 (1.0,1.9), for quintile
5 vs. quintile 1, p-trend=0.026] and hamburger [OR (95% CI): 1.7 (1.3, 2.2), for quartile 4
vs. quartile 1, p-trend=<0.001] cooked at high temperature, well-done red meat [OR (95%
CI): 1.4 (1.1, 1.8), for quartile 4 vs. quartile 1, p-trend=0.013], and pan-fried red meat [OR
(95% CI): 1.3 (1.0,1.8), for quartile 4 vs. quartile 1, p-trend=0.035] were found to increase
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the risk of advanced prostate cancer (Joshi et al., 2012). These results were confirmed by a
study in which an increased risk was observed for high intakes of grilled beef, well-done
beef, and well-done hamburger (Punnen et al., 2011). In addition, intake of MelQx [OR
(95% CI): 1.69 (1.08, 2.64), for quartile 4 vs. quartile 1, p-trend=0.02] and DiMelQX [OR
(95% CI): 1.53 (1.00, 2.35), for quartile 4 vs. quartile 1, p-trend=0.005] were associated
with an elevated risk of aggressive prostate cancer (clinical stage III/IV tumors or Gleason
score ≥7) (Punnen et al., 2011). However, Amin et al, found no association for intakes of red
meat, ham and sausage (analyzed as one group), and chicken with the risk of aggressive
prostate cancer (Amin et al., 2008).
Cohort Studies—Cohort studies conducted to date overall revealed a modest, inconsistent
association between intake of meat and meat products and the risk of advanced prostate
cancer (Table 1). Total meat consumption was weakly associated with a significantly
reduced risk of advanced prostate cancer in one study (Koutros et al., 2008). An inverse but
insignificant association was detected between intake of total unprocessed red meat and the
risk of lethal prostate cancer (Richman et al., 2011).
Although the results on the associations of red or white meat consumption with advanced
prostate cancer risk were conflicting, most studies suggested that high intakes of meats
cooked at high temperature significantly increased risk (Cross et al., 2005; John et al., 2011;
Koutros et al., 2008; Sander et al., 2011; Schuurman et al., 1999; Wright et al., 2011).
Intakes of red meat, processed meat, heme iron, nitrite/nitrate (derived from meat, grilled or
barbecued meat), and B[a]P conferred an elevated risk of advanced prostate cancer in one
study (Sinha et al., 2009). However, dietary iron was not associated with the risk of
advanced prostate cancer in another study (Choi et al., 2008). It has been also reported that
intake of well-done meat was associated with an approximately two-fold increased risk of
advanced disease in a dose-response manner [RR (95% CI): 1.97 (1.26, 3.08), for tertile 3
vs. tertile1, p-trend 0.004) (Koutros et al., 2008). Increased risk associated with consumption
of very well done or strongly browned meat was not statistically significant in other studies
(Cross et al., 2005; Sander et al., 2011). Hamburger intake was not associated with risk of
advanced prostate cancer (Koutros et al., 2008). In addition, intakes of PhIP, MeIQx, and
DiMeIQx did not significanlty influence the risk of advanced prostate cancer in a European
study (Sander et al., 2011).
The effect of total protein intake was examined but no significant association was found
with the risk of advanced prostate cancer, and null results were also obtained for the
association between intakes of animal, dairy, and plant proteins and the risk of advanced
prostate cancer (Allen et al., 2008). Liver intake was significantly associated with a reduced
risk of advanced prostate cancer [RR (95% CI); 0.79 (0.63, 0.99), for quartile 4 vs. quartile
1] in a Dutch study (Schuurman et al., 1999).
2. Fat
Case-Control Studies—Case-control studies have consistently revealed that intake of
total fat and particularly saturated fat was significantly associated with an increased risk of
advanced prostate cancer (Bairati et al., 1998; De Stefani et al., 2000; Slattery et al., 1990;
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Whittemore et al., 1995) (Table 2). Dietary intake of monounsaturated fat (Bairati et al.,
1998; De Stefani et al., 2000), polyunsaturated fat (Agalliu et al., 2011; Bairati et al., 1998),
linoleic acid, and linolenic acid (Bairati et al., 1998; De Stefani et al., 2000) were generally
not associated with advanced prostate cancer risk. When the type and source of linolenic
acid were considered, α-linolenic acid and linolenic acid from animal sources (De Stefani et
al., 2000) were positively and significantly associated with advanced prostate cancer risk.
Higher intake of animal fat was positively associated with the risk of advanced prostate
cancer (Bairati et al., 1998; Hayes et al., 1999), whereas a borderline inverse association was
observed for total vegetable fat [OR (95% CI): 0.58 (0.32, 1.03), for quartile 4 vs. quartile 1]
(Bairati et al., 1998).
Cohort Studies—To our knowledge, only one cohort study has examined fat intake in
relation to the risk of advanced prostate cancer. Phytanic acid is a saturated fatty acid
present predominantly in red meat and dairy products. Higher phytanic acid intake was
associated with an elevated risk of advanced prostate cancer [RR (95% CI): 1.38 (1.02, 1.89)
for quartile 4 vs quartile 1] (Wright et al., 2011).
3. Calcium, Vitamin D, and Dairy Products
Case-Control Studies—Dairy products are rich sources of calcium and vitamin D
(Rowland et al., 2011). At the time this review was prepared, only one case-control study
had investigated the association between calcium intake and advanced prostate cancer risk
(Table 3). High calcium intake was associated with an over two-fold increased risk of
advanced prostate cancer [OR (95% CI): 2.08 (1.22, 3.53) for quartile 4 vs. quartile 1)
(Rowland et al., 2011). Similar results were obtained when total intake of calcium from both
diet and supplements was used in the analysis (Rowland et al., 2011). No association was
found between intake of dairy products and the risk of advanced prostate cancer (Amin et
al., 2008).
Cohort Studies—While most cohort studies suggested that high calcium intake increased
the risk of advanced prostate cancer, the effects of milk and other dairy products on
aggressive prostate tumors were inconsistent across those studies (Table 3). Schuurman et
al., reported no association between intake of milk and milk products and the risk of
advanced prostate cancer (Schuurman et al., 1999). However, a significant positive
association with calcium intake was observed in another study [RR (95% CI); 1.62 (1.08,
2.43), for quartile 4 vs. quartile] (Wright et al., 2011). This finding was confirmed by a large
cohort study (Giovannucci et al., 1998). In the latter study, high calcium consumption
significantly increased the risk of advanced prostate cancer [RR (95% CI): 2.97 (1.61, 5.50),
for ≥2,000 mg/day vs. < 500 mg/day intake, p-trend = 0.002] (Giovannucci et al., 1998). In a
prospective cohort study in which 1,426 cases of advanced prostate cancer was accrued
during 6-years of follow-up, a positive but insignificant association was observed between
total calcium intake and advanced prostate cancer (Park et al., 2007). Two other studies did
not reveal the positive association of total calcium and dietary and supplemental calcium
with the risk of advancced prostate cancer (Ahn et al., 2007; Allen et al., 2008).
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The associations of other dairy products with the risk of advanced prostate cancer was also
evaluated in many studies. Skim milk was associated with an elevated risk of advanced
prostate cancer [RR (95% CI): 1.23 (0.99, 1.64), for >2,000 mg/day vs <500 mg/day intake,
p-trend = 0.01] (Park et al., 2007). However, intake of low-fat milk did not alter the risk of
advanced prostate cancer (Schuurman et al., 1999) or even reduced risk (Wright et al.,
2011). In a Dutch population, significant positive association was detected between intakes
of butter and cheese and the risk of advanced prostate cancer (Wright et al., 2011). In the
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Prevention Trial, intakes of total
dairy, low fat dairy, and high fat dairy products did not influence the risk of aggressive
prostate cancer (Ahn et al., 2007). Furthermore, intakes of calcium from dietary and
supplemental sources did not alter the risk of aggressive prostate cancer (Ahn et al., 2007).
In only one study, the association between vitamin D and advanced prostate cancer was
examined, with null results reported (Giovannucci and Clinton, 1998).
4. Fruits, Vegetables, and Vitamins
Case-Control Studies—A few case-control studies have reported an overall inverse
association between intakes of fruits and vegetables and the risk of advanced prostate cancer
(Table 4). Kolonel et.al. reported that intake of all vegetables were associated with a 33%
reduced risk of advanced prostate cancer (Kolonel et al., 2000). This protective effect was
confined to yellow-green vegetables, cruciferous vegetables, and carrots (Kolonel et al.,
2000). Intake of fruits did not modulate the risk of advanced prostate cancer (Kolonel et al.,
2000). When aggressive prostate cancer was considered, only leafy vegetables [OR (95%
CI): 0.66 (0.46, 0.96), for quartile 4 vs quartile 1, p-trend=0.02] were found to be protective
(Hardin et al., 2011). Intake of all vegetables, carotenoid-rich vegetables, all fruits
(excluding juice), and vitamin C were marginally significantly associated with a reduced
risk of aggressive prostate cancer (p-trend = 0.04 for all vegetables) (Hardin et al., 2011).
However, the aforementioned potential benefits conferred by vegetable consumtion were not
observed in another case-control study (Amin et al., 2008).
Cohort Studies—The results from cohort studies examining the association between
intakes of fruit and vegetables and the risk of advanced prostate cancer were largely
inconsistent (Table 4). In a cohort study, fruit intake was inversely associated with the risk
of advanced prostate cancer [RR (95%): 0.63 (0.43, 0.93), for > 5 vs. ≤1 serving/day].
However, this inverse association was primarily accounted for by fructose intake [RR (95%)
CI: 0.51 (0.33, 0.80), for >70 g vs. ≤40 g/day, p-trend = 0.007) (Giovannucci et al.,
1998).Takachi et al did not find any association of fruit intake with the risk of advanced
prostate cancer (Takachi et al., 2010). Most cohort studies did not reveal that intakes of total
vegetables, green leafy vegetables, yellow vegetables, cruciferous vegetables, and fruits
protected against advanced prostate cancer (Agalliu et al., 2011; Giovannucci et al.,
2003;Takachi et al., 2010).
Micronutrinets abound in fresh vegetables and fruits. Several studies have examined the
association between micronutrients and advanced prostate cancer. It was reported that higher
intakes of menaquinones (vitamin K2) (Nimptsch et al., 2008), α-tocopherol (Weinstein et
al., 2007), γ-tocopherol, and δ-tocopherol (Wright et al., 2007) were associated with a lower
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risk of advanced prostate cancer. Similar protective effect for advanced disease was
observed for high plasma concentrations of total carotenoids (including α-carotene, β-
carotene, β-cryptoxanthin, canthaxanthin, lutein, lycopene, and zexanthin) in the European
Prospective Investigation into Cancer and Nutrition Study (Key et al., 2007). However, null
results were obtained for vitamin C, β-carotene, β-cryptoxanthin, lutein/zexanthin, selenium,
phylloquinone (vitamin K1), and folate in some other studies (Agalliu et al., 2011; Nimptsch
et al., 2008; Stevens et al., 2006; Weinstein et al., 2007). The influence of vitamin
supplement use on prostate cancer has been also evaluated (Lawson et al., 2007). In the
NIH-AARP Diet and Health Study, men who reported an excessive use of multivitamins
experienced a significantly increased risk of advanced prostate cancer [RR (95%): 1.32
(1.04, 1.67), for quartile 4 vs. quartile 1] (Lawson et al., 2007). However, some individual
micronutrients (vitamin E, selenium, and folate] were not associated with the risk of
advanced prostate cancer in the same study (Lawson et al., 2007). Similar null results were
found for nutrients involved in one-carbon metabolism (folate, vitamin B2, vitamin B6,
vitamin B12, and methionine) in another cohort study (Kasperzyk et al., 2009).
5. Lycopene and Tomato Products
There is a growing body of evidence that lycopene has a beneficial effect on prostate cancer
(Dahan et al., 2008; Haseen et al., 2009). Lycopene may suppress prostate carcinogenesis
through decreasing lipid oxidation, enhancing antioxidant capacities, and inhibiting cell
proliferation (Wei and Giovannucci 2012). The association between lycopene intake and
advanced prostate cancer has been evaluated in several studies (Table 5). Giovannucci et.al.
reported an inverse association between tomato sauce intake and advanced prostate cancer
risk (Giovannucci et al., 2002). In an European study, plasma concentrations of lycopene
were associated with a 60% reduced risk of advanced prostate cancer [RR 95% CI: 0.40
(0.19, 0.88) for quintile 5 vs. quintile 1] (Key et al., 2007). It should be pointed out that
protective effect on advanced prostate cancer was not detected in some other studies for
intake of lycopene (Agalliu et al., 2011; Kirsh et al., 2006), tomatoes and tomato products
(Takachi et al., 2010), and other tomato-based food products (pizza, lasagna, and spagghetti)
(Kirsh et al., 2006).
6. Other dietary factors
Other dietary factors in relation to advanced prostate cancer are briefly summarized below
due to the relative scarcity of data available from epidemiologic studies.
Fish—Three cohorts conducted in the Netherlands (Schuurman et al., 1999), USA
(Augustsson et al., 2003), and Finland (Wright et al., 2011) showed that fish consumption
did not influence the risk of advanced prostate cancer. However, a significantly reduced risk
of metastatic prostate cancer associated with fish consumption was observed in a US cohort
[RR (95% C.I): 0.56 (0.37, 0.86), for quartile 4 vs. quartile 1] (Augustsson et al., 2003).
Tea—A number of animal studies have demonstrated that green tea extracts (including
polyphenols and catechins) inhibit the growth of prostate tumor (Henning et al., 2011;
Siddiqui et al., 2006). This anticarcinogenic effect has been extensively reviewed in a meta-
analysis (Zheng et al., 2011). To our knowledge, only one epidemiologic study has
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investigated the effect of tea consumption on prostate cancer risk (Kurahashi et al., 2008). In
that cohort study among Japanese men, green tea consumption was associated with a 48%
reduced risk of advanced prostate cancer after adjustment for confounders [RR (95% CI):
0.52 (0.28-0.96) for quintile 5 vs. quintile 1] (Kurahashi et al., 2008). In a randomized
chemoprevention trial among 60 volunteers with high-grade prostate intraepithelial
neoplasia (precursors of prostate cancer), men who received 600 mg/day of green tea
catechins experienced a significant lower risk of prostate cancer than those who received
placebo after one-year follow-up (incidence: 3.3% in intervention vs. 30% in placebo,
p<0.01) (Bettuzzi et al., 2006).
Zinc—In a case-control study reported by Gallus et.al, zinc intake was not associated with
an altered risk of advanced prostate cancer (Gallus et al., 2007), but a potentially reduced
risk was found in a cohort study [RR (95% CI): 0.67 (0.41, 1.10), for quartile 4 vs. quartile
1] (Epstein et al., 2011). This insignificant benefit was also observed for intake of zinc from
supplements for both aggressive prostate cancer [RR (95% CI): 0.70 (0.41, 1.19), for
quartile 4 vs. quartile 1)] and metastasized cancer [RR (95% CI): 0.34 (0.13, 1.09), for
quartile 4 vs. quartile 1] (Gonzalez et al., 2009).
Dietary Patterns—In addition to the evaluation of individual nutrients and specific foods,
a few case-control studies have investigated whether dietary patterns play a role in the
etiology of prostate cancer. The Western diet, characterized by high intake of energy, red
meats, and fat and low intake of fiber, has been associated with an increased risk of
advanced prostate cancer in an Australian study [OR (95% CI): 2.11 (1.25, 3.60), for
quartile 4 vs. quartile 1, p-trend=<0.01] (Ambrosini et al., 2008) and an Uruguayan study
[OR (95% CI): 2.35 (1.44, 3.85), for quartile 4 vs. quartile 1, p-trend=<0.0001] (De Stefani
et al., 2010), but not in an American study (Wu et al., 2006).
Discussion
Epidemiologic evidence overall suggests that the habitual consumption of a diet high in
saturated fat, well-done meats, and calcium conferred an increased risk of advanced prostate
cancer. The effects of other nutrients and foods on the development of advanced prostate
cancer were largely inconsistent across epidemiologic studies.
A number of epidemiologic studies have shown that intakes of total meats and white meats
are not associated with the risk of advanced prostate cancer (Alexander et al., 2010).
However, methods for cooking meats should be considered when meat consumption is
evaluated for its effect on prostate carcinogenesis. Most, although not all, epidemiologic
studies have consistently revealed that intakes of well-done meats and mutagens derived
from meats cooked at high temperature (e.g. grilled, fried, and barbecued meats) were
associated with a significantly elevated risk of advanced prostate cancer in a dose-response
manner (p-trend ≤0.01 for well-done meats for most studies) (Koutros et al., 2008; Punnen
et al., 2011; Sinha et al., 2009). The ORs or RRs for the highest vs. lowest categories of
intake of well-done meats ranged from 1.28 to 2.16 (Cross et al., 2005; Joshi et al., 2012;
Koutros et al., 2008; Punnen et al., 2011; Sinha et al., 2009). The potential role of well-done
meats in prostate cancer etiology is biologically plausible because prostate tumors have been
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induced in rats fed on a meat-derived mutagen (PHiP) (Shirai et al., 1997). Furthermore,
PhIP-DNA adducts that may cause DNA mutations and initiate carcinogenesis were detected
in all lobes of the prostate of rats receiving PhIP in the same study (Shirai et al., 1997).
As mentioned previously, ecologic and migrant studies strongly suggest that intake of fat
and especially animal fat (primarily saturated fat) was associated with an increased risk of
prostate cancer (Rose et al., 1986; Whittemore et al., 1995). This obsevation has gained
further support from increasing trends in prostate cancer incidence in East Asia over last few
decades probably as a consequence of nutrition transition toward the Western diet (Zhang et
al., 2012). However, the results from analytical epidemiologic studies on the effect of fat
and types of fat on prostate cancer risk were mixed. Most case-control studies have shown a
significant, positive association between intakes of total fat and especially saturated fat and
the risk of advanced prostate cancer, with risk estimates (ORs) ranged from 1.4 to 8.7
(Bairati et al., 1998; De Stefani et al., 2000; Whittemore et al., 1995). A number of animal
studies suggest that fat is implicated in prostate carcinogenesis by promoting oxidative stress
and inflammation in the prostate gland (Hill, 1987; Vykhovanets et al., 2011).
To date, one case-control study has demonstrated that dietary intake of calcium was
monotonically associated with an increased risk of advanced prostate cancer (p-trend =
0.001) (Rowland et al., 2011). Similar but less consistent results were obtained from cohort
studies. Vitamin D was not associated with an elevated risk of advanced prostate cancer
(Giovannucci and Clinton, 1998). Vitamin D enhances the absorption of calcium in the gut.
Experimental studies have demonstrated that vitamin D promotes the differentiation and
suppresses the proliferation of prostate cells (Samuel and Sitrin, 2008). It has been put
forward that high calcium intake increases the risk of prostate cancer through reducing
circulating levels of 1,25-dihydroxyvitamin D, most active form of this vitamin (Williams et
al., 2012).
Most case-control studies have demonstrated a significant, inverse association between
intakes of vegetables (yellow-green, cruciferous, carrots, and legumes) and the risk of
advanced prostate cancer, with risk estimates (ORs) ranged from 0.36 to 0.96 (Hardin et al.,
2011; Kolonel et al., 2000). However, no association was found between intake of
vegetables and the risk of advanced prostate cancer in most cohort studies (Agalliu et al.,
2011; Stevens et al., 2006; Takachi et al., 2010). Similarly, fruit intake was overall not
associated with the risk of advanced prostate cancer in both case-control (Amin et al., 2008;
Hardin et al., 2011; Kolonel et al., 2000) and cohort studies (Takachi et al., 2010). Excessive
use of multivitamins increases the risk of advanced prostate cancer (Lawson et al., 2007).
Vitamin E naturally occurs in eight chemical forms that include tocopherols and tocotrienols
(Jiang et al., 2001); α -, γ-, and δ-tocopherol intake has been significantly associated with a
reduced risk of advanced prostate cancer, with reported risk estimates (RRs) being from 0.36
to 0.96 (Weinstein et al., 2007; Wright et al., 2007). Vegetables and fruits contain a variety
of chemical compounds including vitamin C, carotenoids, flavonoids, phenols, and fiber.
These molecules possess antioxidant properties, bind and dilute carcinogens, or alter
hormone metabolism (McDermott, 2000), which offers biochemical mechanisms for the
protective effect of vegetables and fruits on prostate cancer.
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Lycopene is derived largely from tomatoes and tomato-based products (Dahan et al., 2008).
As experimental studies have provided ample evidence supporting that lycopene has
anticarcinogenic properties that have been mentioned previously, a number of epidemiologic
studies have investigated its effect on total prostate cancer (Etminan et al., 2004). A meta-
analysis showed a modest inverse association between lycopene intake and the risk of total
prostate cancer (Etminan et al., 2004). Among a few studies that reported risk estimates for
advanced prostate cancer, a significantly reduced risk was observed for men who exhibited
high plasma concentrations of lycopene in an European cohort study (Key et al., 2007).
However, this protective effect was not detected in other cohort studies based on the analysis
of dietary intake of lycopene (Agalliu et al., 2011; Kirsh et al., 2006). It has been reported
that lycopene from raw and cooked tomatoes have different intestinal bioavailability
(Gartner et al., 1997), which may offer a partial explanation for the null effect of dietary
lycopene on advanced prostate cancer.
The results obtained from epidemiologic studies of dietary patterns in relation to disease risk
are more directly applicable to dietary recommendations than those from studies of
individual nutrients because people can manipulate nutrient intake by their choice of foods.
Two case-control studies have shown that maintaining a Western diet pattern was
significantly associated with an over two-fold elevated risk of advanced prostate cancer in a
dose-response manner (p-trend < 0.001) (Ambrosini et al., 2008; De Stefani et al., 2010).
Similar results were not observed from a cohort study (Wu et al., 2006). In addition, other
dietary patterns (e.g. a prudent dietary pattern) were not found to influence the risk of
advanced prostate cancer (De Stefani et al., 2010; Wu et al., 2006). Collectively, more
epidemiologic studies are encouraged to evaluate the effect of various dietary patterns on the
occurrence of total and particularly aggressive prostate cancer because of the importance
and relevance of research in this area for cancer etiology, prevention, and control.
Several factors might have contributed to observed inconsistent results of some nutrients and
foods in relation to advanced prostate cancer. To date, most studies on this topic have
examined total prostate cancer only. In the studies that reported separate results for
advanced tumors, the number of advanced prostate cases was generally small, which offer
inadequate statistical power to detect modest effects. In addition, scarce data are available on
the effect of diet on the risk of aggressive and metastatic prostate cancer. Measured and
unmeasured confounding should be considered in the interpretation of results obtained from
any epidemiologic studies. Although age, race, and family history were treated as
confounders in most studies, adjustment for other potential confounding factors were
different among reviewed studies. Last, food frequency questionnaire has been used in the
majority of nutritional epidemiologic studies over last two decades. A number of validation
studies have shown that underreporting of fat and meats and over reporting of vegetables
and fruits intake are common among these studies (Macdiarmid and Blundell, 1998). These
dietary measurement errors could result in misclassification of subjects with regard to their
dietary intakes of nutrients and foods and consequently the attenuation of true associations
of dietary factors with the risk of advanced prostate cancer (Bingham et al., 2003). Recall
bias inherent in food frequency questionnaire could be overcome by measuring biochemical
indicators of nutrients in various biological specimens (e.g. blood, urine, and tissue).
However, these nutritional biomarkers were not determined in most epidemiologic studies.
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In summary, epidemiologic studies conducted to date overall suggest that high intakes of
saturated fat, meats cooked at high temperature, and calcium are associated with an
increased risk of advanced prostate cancer. It should be noted that these results were largely
based on a relatively small number of advanced prostate tumors in most epidemiologic
studies reviewed. More adequately-powered epidemiologic studies (especially prospective
cohort studies) that measure both dietary intake of nutrients and their biomarkers are
warranted to further elucidate the role of diet in the etiology of advanced prostate cancer. As
dietary factors are modifiable, identifying nutrients or food groups that modulate the risk of
advanced prostate cancer can offer effective and practical strategies for its primary
prevention.
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Figure 1. Flowchart of selecting papers included in this review
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